Abcam to be Acquired by Danaher for $5.7 Billion
<p><a href='https://financialmodelingprep.com/financial-summary/DHR'>Danaher Corporation (NYSE:DHR)</a> and <a href='https://financialmodelingprep.com/financial-summary/ABCM'>Abcam (NASDAQ:ABCM)</a> announced a definitive agreement for acquisition. In this deal, Danaher will acquire all currently outstanding shares of Abcam at a cash price of $24.00 per share. The total value of the acquisition stands at approximately $5.7 billion, accounting for assumed debts and subtracting acquired cash.</p>
<p>Upon completion, Abcam is expected to maintain its independent operational status and retain its unique brand identity within Danaher's Life Sciences segment.</p>
<p>The transaction is set to close in mid-2024. Danaher intends to finance the acquisition through available cash and proceeds from the issuance of commercial paper.</p>

NYSE:DHR, NASDAQ:ABCM